(Q37844529)

24 August 2017

1 reference

title

A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer (English)

1 reference

24 August 2017

1 reference

1 reference

1 reference

Giannis Mountzios

1

1 reference

24 August 2017

Kostas N Syrigos

series ordinal

2

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

34

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

175-186

1 reference

24 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Toxicity of targeted therapy in non-small-cell lung cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586540-000000000-00000

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

21 January 2018

1 reference

12 December 2020

Lessons learned in the management of advanced pancreatic cancer

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

1 reference

12 December 2020

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

12 December 2020

Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma

1 reference

12 December 2020

Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

1 reference

12 December 2020

Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma

1 reference

12 December 2020

10.2165/11586540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1046235533

0 references

1 reference